{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,30]],"date-time":"2025-11-30T09:19:47Z","timestamp":1764494387622,"version":"3.45.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Carfilzomib, a second-generation proteasome inhibitor, is approved for the treatment of relapsed or refractory multiple myeloma, with cardiovascular toxicity being the most common concern. Nevertheless, pulmonary complications have been reported and may complicate differential diagnosis. We describe the case of a 79-year-old man with multiple myeloma who developed two episodes of acute respiratory failure temporally related to carfilzomib administration. After six cycles of therapy, the patient presented with dyspnea, hypoxemia, and bronchospasm requiring hospitalization. Extensive investigations excluded infection, pulmonary embolism, and cardiac dysfunction, and symptoms resolved with supportive therapy. Carfilzomib was resumed at reduced dose, but a second episode of respiratory failure occurred shortly after re-exposure, leading to definitive discontinuation. Pulmonary function testing demonstrated recovery to baseline values after drug withdrawal. This case underlines the need for awareness of non-cardiogenic respiratory adverse events in patients treated with carfilzomib, especially those with pre-existing pulmonary conditions. Careful monitoring and appropriate diagnostic work-up are essential, and drug re-challenge should be avoided in case of severe respiratory events. Recognition of these complications may improve patient safety and guide therapeutic decisions in multiple myeloma.<\/jats:p>","DOI":"10.3389\/fonc.2025.1701639","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:19:56Z","timestamp":1762924796000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Iatrogenic dyspnea and respiratory failure in a multiple myeloma patient treated with carfilzomib"],"prefix":"10.3389","volume":"15","author":[{"given":"Giuseppe","family":"Bertuglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mattia","family":"Verardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matilde","family":"Scaldaferri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro","family":"Mangiapia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benedetto","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Larocca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.740796","article-title":"Carfilzomib: A promising proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma","volume":"11","author":"Jayaweera","year":"2021","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomized, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2499","article-title":"Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials","volume":"36","author":"Mateos","year":"2018","journal-title":"Hematol Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023010026","article-title":"Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study","volume":"7","author":"Usmani","year":"2023","journal-title":"Blood Adv"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00592-4","article-title":"Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicenter, open-label, randomized phase 3 trial","volume":"397","author":"Moreau","year":"2021","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/joim.12882","article-title":"Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension","volume":"286","author":"Bringhen","year":"2019","journal-title":"J Intern Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomized, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2322030","article-title":"An open-label phase 2 study treating patients with first or second relapse of multiple myeloma with carfilzomib, pomalidomide, and dexamethasone (KPd): SELECT study","volume":"65","author":"Perrot","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B9","first-page":"24","article-title":"Overview and management of cardiac and pulmonary adverse events in patients with relapsed and\/or refractory multiple myeloma treated with single-agent carfilzomib","volume":"27","author":"Wang","year":"2013","journal-title":"Oncol (Williston Park)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"492A","DOI":"10.1016\/j.chest.2016.08.506","article-title":"Carfilzomib pulmonary toxicity","volume":"150","author":"Bhagavath","year":"2016","journal-title":"Chest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215588630","article-title":"Fatal pulmonary toxicity due to carfilzomib (Kyprolis\u2122)","volume":"22","author":"Lataifeh","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e251173","DOI":"10.1136\/bcr-2022-251173","article-title":"Severe pulmonary toxicity related to carfilzomib use: a rare but serious side effect","volume":"15","author":"Sridhar","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32601","article-title":"Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database","volume":"126","author":"Fakhri","year":"2020","journal-title":"Cancer"},{"key":"B14","unstructured":"FDA adverse event reporting system (FAERS) public dashboard"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122245","article-title":"Lactoferrin ameliorates carfilzomib-induced renal and pulmonary deficits: Insights to the inflammasome NLRP3\/NF-\u03baB and PI3K\/Akt\/GSK-3\u03b2\/MAPK axes","volume":"335","author":"Habib","year":"2023","journal-title":"Life Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2018.11.023","article-title":"Apremilast ameliorates carfilzomib-induced pulmonary inflammation and vascular injuries","volume":"66","author":"Al-Harbi","year":"2019","journal-title":"Int Immunopharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41408-023-00885-9","article-title":"Carfilzomib-induced thrombotic microangiopathy (TMA): an under-recognized spectrum of disease from microangiopathic hemolysis to subclinical TMA","volume":"13","author":"Ponraj","year":"2023","journal-title":"Blood Cancer J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20458940211049300","article-title":"Carfilzomib-associated pulmonary arterial hypertension in multiple myeloma","volume":"11","author":"Yang","year":"2021","journal-title":"Pulm Circ"},{"key":"B19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12931-019-1133-8","article-title":"Dysregulation of the endothelial nitric oxide pathway is associated with airway inflammation in COPD","volume":"20","author":"Csoma","year":"2019","journal-title":"Respir Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"OA3572","DOI":"10.1183\/13993003.congress-2019.OA3572","article-title":"The effect of inhaled nitric oxide on dyspnea and exercise capacity in mild COPD","author":"Phillips","year":"2019","journal-title":"Clin Respir physiology Exercise Funct Imaging"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-915","article-title":"Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring","volume":"14","author":"Chari","year":"2014","journal-title":"BMC Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2023-177546","article-title":"Results of the phase III randomized iskia trial: isatuximab-carfilzomib-lenalidomide-dexamethasone vs carfilzomib-lenalidomide-dexamethasone as pre-transplant induction and post-transplant consolidation in newly diagnosed multiple myeloma patients","volume":"142","author":"Gay","year":"2023","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02266","article-title":"satuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial","volume":"43","author":"Mai","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1701639\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T05:19:58Z","timestamp":1762924798000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1701639\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":25,"alternative-id":["10.3389\/fonc.2025.1701639"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1701639","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"article-number":"1701639"}}